Lifeloc Completes SpinDetect(TM) Disk Production Tooling, Commissions Cleanroom, and Outlines Staged Commercial Rollout

Rhea-AI Summary

Lifeloc (OTC:LCTC) reported progress on its SpinDetect drug analyzer and core breath alcohol business. The company completed production tooling for SpinDetect consumable disks, produced and tested first-article disks, and commissioned a cleanroom with an automated reagent-dispensing robot, shifting the program into validation and early production.

Lifeloc plans a staged SpinDetect rollout, initially targeting U.S. forensic and permitted international markets, with workplace access after FDA clearance. The first product will be a qualitative delta-9-THC test, with launch anticipated in late 2026 or early 2027 and a reader list price around $7,495.

AI-generated analysis. Not financial advice.

Positive

• SpinDetect disk production tooling completed and first-article disks tested
• Cleanroom with automated reagent-dispensing robot commissioned for validation and early production
• Staged commercialization plan targeting U.S. forensic and international markets first
• First SpinDetect product focused on qualitative delta-9-THC testing
• Commercial launch anticipated in late 2026 or early 2027
• SpinDetect reader initially priced around $7,495 in the U.S.
• Ongoing investment in L-series breath alcohol platform, including OIML-variant LX9 for international markets

Negative

• SpinDetect commercial launch not expected until late 2026 or early 2027
• Access to U.S. workplace testing market dependent on obtaining FDA clearance

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WHEAT RIDGE, CO / ACCESS Newswire / June 15, 2026 / Lifeloc Technologies, Inc. (OTC PINK:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, today provided an update on its SpinDetect^™ Centrifugal Drug Analyzer program and its core breath alcohol business.

Lifeloc has completed the production mold for the SpinDetect consumable test disks and produced first-article disks, which have undergone initial testing. Minor mold modifications identified during that testing have been completed, and new production disks are now available for continued validation. To support validation and initial manufacturing, the company has commissioned a cleanroom equipped with an automated reagent-dispensing robot - moving the program from development into validation and early production.

Lifeloc intends to bring SpinDetect to market in deliberate stages. Initial commercialization will target the U.S. forensic testing market and international markets where permitted; access to the U.S. workplace testing market will follow receipt of FDA clearance. The first commercial product will be a qualitative pass/fail test for delta-9-THC, the primary psychoactive component of marijuana, with quantitative delta-9-THC disks and a multi-drug panel expected to follow. Preliminary testing may also support an earlier release into selected lower-complexity, non-forensic applications such as veterinary testing.

The Company currently anticipates commercial launch in late 2026 or early 2027. The SpinDetect reader is expected to be offered at an initial U.S. list price of approximately $7,495, with single-use test disks priced separately.

Reflecting feedback from law enforcement customers - who have emphasized the importance of a meaningful margin above legal thresholds to support defensible results - the initial delta-9-THC product is expected to launch at a detection threshold above the 4 ng/mL oral-fluid cutoff referenced in certain federal guidelines, with the Company intending to pursue lower detection limits following launch. Lifeloc believes the SpinDetect analyzer's ability to isolate psychoactive delta-9-THC from its inactive metabolites - distinguishing recent use from prior use - remains a key differentiator versus existing screening devices.

In its core breath alcohol business, Lifeloc continues to invest in its L-series platform, including development of an OIML-variant of its LX9 device intended to broaden addressable international markets while incorporating cost-of-goods improvements. While the SpinDetect platform is designed to support a range of future assays, the Company's current development focus is drugs of abuse, and Lifeloc views performance-enhancing drug testing as the most natural adjacency for future expansion.

"Completing our disk production tooling and standing up a cleanroom are the steps that turn SpinDetect from a development program into a product," said Dr. Wayne Willkomm, President and CEO of Lifeloc. "We're taking a disciplined, staged approach - prove the technology in forensic and international markets first, then broaden the drug menu and pursue the workplace and federal opportunities. The ability to accurately measure impairing delta-9-THC, discriminated from its metabolites, is why we believe this platform can ultimately help set the standard for roadside and workplace drug testing."

An updated corporate presentation is also available on the Company's investor relations website at https://lifeloc.com/investor.

About Lifeloc Technologies

Lifeloc Technologies, Inc. (OTC:LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, www.lifeloc.com.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties, including those described in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission, that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, expectations about new and existing products, our ability to fund operations and product development, market demand, acceptance of new and existing products, technologies and opportunities, development and commercialization timelines, market size and growth, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled "Risk Factors" in our SEC filings.

Phoenix^® and Easycal^® are registered trademarks of Lifeloc Technologies, Inc.

SpinDetect^™ is a trademark of Lifeloc Technologies, Inc.

Amy Evans
Lifeloc Technologies, Inc.
http://www.lifeloc.com
(303) 431-9500

SOURCE: Lifeloc Technologies, Inc.

View the original press release on ACCESS Newswire

FAQ

What did Lifeloc (OTC:LCTC) announce about SpinDetect production on June 15, 2026?

Lifeloc announced completion of SpinDetect disk production tooling, initial disk testing, and commissioning of a dedicated cleanroom. According to Lifeloc, these steps move SpinDetect from a development program into validation and early production, supporting upcoming commercialization efforts and assay expansion plans.

When is Lifeloc's SpinDetect drug analyzer expected to launch commercially?

Lifeloc currently anticipates a SpinDetect commercial launch in late 2026 or early 2027. According to Lifeloc, the rollout will begin with U.S. forensic testing and permitted international markets, with U.S. workplace testing access following receipt of required FDA clearance.

Which markets will Lifeloc's SpinDetect initially target and what is the first test?

SpinDetect will first target the U.S. forensic testing market and international markets where permitted. According to Lifeloc, the initial commercial product will be a qualitative pass/fail delta-9-THC test, with quantitative delta-9-THC and multi-drug panels planned afterward.

How is Lifeloc pricing the SpinDetect reader and test disks for investors to consider?

The SpinDetect reader is expected to have an initial U.S. list price of about $7,495. According to Lifeloc, single-use test disks will be sold separately, creating a recurring consumables revenue stream once commercial sales begin in late 2026 or early 2027.

What technical advantages does Lifeloc highlight for the SpinDetect delta-9-THC assay?

SpinDetect is described as isolating psychoactive delta-9-THC from inactive metabolites to indicate recent use. According to Lifeloc, this discrimination may help distinguish impairment from prior use and support more defensible roadside and workplace oral-fluid drug testing decisions.

What updates did Lifeloc (LCTC) provide on its core breath alcohol business?

Lifeloc continues investing in its L-series breath alcohol platform, including an OIML-variant LX9 device. According to Lifeloc, this variant aims to broaden international market reach while improving cost of goods, complementing the SpinDetect drugs-of-abuse development focus and potential future performance-enhancing drug assays.

How will Lifeloc stage the commercial rollout of the SpinDetect platform?

Lifeloc plans a disciplined, staged SpinDetect rollout, proving the technology in forensic and international markets first. According to Lifeloc, the company will then broaden the drug menu and pursue U.S. workplace and federal opportunities as validation, regulatory clearances, and product extensions progress.